Alnylam today announced the addition of RNA interference therapies for the hepatitis delta virus and chronic liver infections to its clinical pipeline at the American Association for the Study of Liver Diseases in Boston. The company also said it remains on track to select a candidate for its hepatitis B program by the end of the year and hopes to file an investigational new drug application with the FDA in late 2015.
BOSTON--Talking of breaking internal silos has become a corporate-speak cliche. But in a speech that could be described as brutally honest, GlaxoSmithKline's ($GSK) head of drug delivery nevertheless brought the importance of doing so to life during last week's Partnership Opportunities in Drug Delivery conference. Read more >>
The prospects for Remoxy, the twice-rejected, investigational, extended-release oral formulation of oxycodone, look bleak. Pfizer is pulling out of a partnership with Durect to commercialize the candidate, after reviewing the results of 5 clinical trials conducted in response to the FDA's second complete response letter, issued in 2011. Read more >>
POPULAR COMMENT THREADS
Researchers at the University of California in San Diego have developed a way to disguise the genetic material itself so that it can enter cells and shut down genetic diseases at the core.
Flowonix, maker of the implantable Prometra infusion pump for chronic pain patients, announced that it has raised $40 million in debt and equity financing led by private equity fund Élevage Capital Management.
Delivery giant Catalent bought out Micron Technologies, a company that specializes in particle size engineering. The acquisition gives Catalent a leg up in early-stage drug development, according to a release, adding to its slate of oral and inhaled technologies.
The National Science Foundation this week awarded a second research grant to the maker of the only FDA-cleared catheter for rectal delivery of medication and liquids to expand the device's use beyond the hospice.
Medical marijuana company CannScience Innovations entered into a nonbinding agreement to license Generex Biotechnology's RapidMist device for the buccal delivery of its developmental stage medical marijuana products.
Cynapsus Therapeutics touted the results of its Phase 2 clinical trial of its sublingual thin-film-strip formulation of apomorphine for the management of OFF motor symptoms of Parkinson's disease.
From Our Sister Sites
LabCorp and CareDx have officially pulled the plug on a previously announced agreement to develop a lupus flare predictor test after completing the first phase of their collaboration.
A U.K. consortium led by Zoetis announced a $3 million project that will use visual imaging and digital technology to improve the health and wellness of pig herds with a goal of better production.